Allianz Asset Management GmbH - BIOSPECIFICS TECHNOLOGIES CO ownership

BIOSPECIFICS TECHNOLOGIES CO's ticker is BSTC and the CUSIP is 090931106. A total of 115 filers reported holding BIOSPECIFICS TECHNOLOGIES CO in Q2 2019. The put-call ratio across all filers is - and the average weighting 0.1%.

Quarter-by-quarter ownership
Allianz Asset Management GmbH ownership history of BIOSPECIFICS TECHNOLOGIES CO
ValueSharesWeighting
Q1 2020$1,256,000
-70.3%
22,197
-70.1%
0.00%
-50.0%
Q4 2019$4,227,000
-1.3%
74,228
-7.3%
0.00%0.0%
Q3 2019$4,284,000
-37.1%
80,049
-29.8%
0.00%
-33.3%
Q2 2019$6,809,000
+52.4%
114,034
+59.1%
0.01%
+50.0%
Q1 2019$4,468,000
+12.0%
71,692
+8.8%
0.00%0.0%
Q4 2018$3,991,000
-2.3%
65,864
-5.7%
0.00%0.0%
Q3 2018$4,086,000
+36.9%
69,865
+5.0%
0.00%
+33.3%
Q2 2018$2,984,000
+2.3%
66,512
+1.1%
0.00%0.0%
Q1 2018$2,918,000
+0.8%
65,819
-1.5%
0.00%
+50.0%
Q4 2017$2,895,000
-26.7%
66,804
-21.3%
0.00%
-33.3%
Q3 2017$3,950,000
-5.7%
84,901
+0.3%
0.00%
-25.0%
Q2 2017$4,190,000
+14.8%
84,621
+27.1%
0.00%0.0%
Q1 2017$3,649,000
+11.2%
66,595
+13.0%
0.00%
+33.3%
Q4 2016$3,282,000
+8.1%
58,919
-11.4%
0.00%0.0%
Q3 2016$3,037,000
+6.9%
66,495
-6.5%
0.00%0.0%
Q2 2016$2,842,000
+10.5%
71,149
-3.7%
0.00%0.0%
Q1 2016$2,573,000
-68.3%
73,891
-60.8%
0.00%
-66.7%
Q4 2015$8,108,000
-1.3%
188,681
-0.0%
0.01%
-10.0%
Q3 2015$8,216,000
+75.3%
188,708
+107.7%
0.01%
+100.0%
Q2 2015$4,688,000
+39.9%
90,848
+6.2%
0.01%
+25.0%
Q1 2015$3,350,000
+59.8%
85,570
+57.7%
0.00%
+100.0%
Q4 2014$2,096,000
+201.6%
54,277
+175.5%
0.00%
+100.0%
Q3 2014$695,00019,7000.00%
Other shareholders
BIOSPECIFICS TECHNOLOGIES CO shareholders Q2 2019
NameSharesValueWeighting ↓
JW Asset Management, LLC 73,649$3,646,0002.32%
Stonepine Capital Management, LLC 59,878$2,965,0001.60%
NORTHPOINTE CAPITAL LLC 109,644$5,428,0000.57%
Elk Creek Partners, LLC 145,406$7,199,0000.47%
TFS CAPITAL LLC 18,208$901,0000.35%
RICE HALL JAMES & ASSOCIATES, LLC 161,671$8,004,0000.35%
Ativo Capital Management LLC 19,592$970,0000.26%
Matarin Capital Management, LLC 57,034$2,823,753,0000.26%
ISTHMUS PARTNERS, LLC 16,505$817,0000.24%
Stanley-Laman Group, Ltd. 12,546$621,0000.17%
View complete list of BIOSPECIFICS TECHNOLOGIES CO shareholders